Initial data generated by CX-072, CTMX' PD-L1 prodrug, have failed to woo investors due to the difficulty involved in interpreting data from small dose escalati
A deep pipeline will lead to new drug approvals. AbbVie has a good chance of replacing Humira's revenues during the next couple of years. AbbVie provides a comp
Biogen is a solid biotech company with established revenue streams and strong financials. The short-term growth of the company is heavily dependent on Spinraza'
Eli Lilly & Company (NYSE:LLY) announced that it has filed a new drug application with the FDA for approval of its migraine candidate, lasmiditan.The NDA seeks approval of...
Merck & Co., Inc. (NYSE:MRK) announced that its PD-L1 inhibitor, Keytruda significantly improved overall survival (OS) compared to standard chemotherapy in a phase III study...
Roche Holdings AG (OTC:RHHBY) announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for the label expansion of immuno-oncology...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Sell||Strong Buy|
|Technical Indicators||Neutral||BUY||Strong Buy||BUY||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Down||1M||Current|
|Engulfing Bearish||1M||1||Oct 18|
|Bullish doji Star||1D||1||Nov 15, 2018|
|Three Outside Up||30||3||Nov 16, 2018 10:00AM|
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$2000||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.